CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-06-07 | DENNER ALEXANDER J Director | Grant or award | +1,055 | 10,029 | ||
| 2017-06-01 | Ehlers Michael D EVP, Research and Development | Shares withheld for taxes | −336 | $252.38 | $85K | 2,768 |
| 2017-06-01 | Ehlers Michael D EVP, Research and Development | Exercise or conversion | +1,259 | 4,027 | ||
| 2017-06-01 | Ehlers Michael D EVP, Research and Development | Shares withheld for taxes | −411 | $252.38 | $104K | 3,616 |
| 2017-06-01 | Ehlers Michael D EVP, Research and Development | Exercise or conversion · Restricted Stock Unit | −1,259 | 6,231 | ||
| 2017-06-01 | Ehlers Michael D EVP, Research and Development | Other disposition · Restricted Stock Unit | −1,235 | 4,996 | ||
| 2017-05-02 | Vounatsos Michel Chief Executive Officer | Exercise or conversion | +1,736 | 4,663.46 | ||
| 2017-05-02 | Vounatsos Michel Chief Executive Officer | Shares withheld for taxes | −564 | $271.34 | $153K | 4,099.46 |
| 2017-05-02 | Vounatsos Michel Chief Executive Officer | Exercise or conversion · Restricted Stock Unit | −1,736 | 8,004 | ||
| 2017-05-02 | Vounatsos Michel Chief Executive Officer | Other disposition · Restricted Stock Unit | −1,508 | 6,496 | ||
| 2017-05-01 | Vounatsos Michel Chief Executive Officer | Purchase | +1,402 | $271.35 | $380K | 2,927.46 |
| 2017-04-27 | DENNER ALEXANDER J Director | Purchase | +15,000 | $278.58 | $4.2M | 325,000 |
| 2017-04-27 | DENNER ALEXANDER J Director | Purchase | +58,858 | $278.48 | $16.4M | 383,858 |
| 2017-04-25 | Clancy Paul J Executive VP and CFO | Sale | −9,892 | $290.00 | $2.9M | 10,813 |
| 2017-04-03 | Sandrock Alfred EVP CMO Neuro & Neurodegenerat | Sale | −1,981 | $274.08 | $543K | 7,059.86 |
| 2017-03-13 | Clancy Paul J Executive VP and CFO | Sale | −9,891 | $291.55 | $2.9M | 20,705 |
| 2017-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Exercise or conversion | +481 | 718.44 | ||
| 2017-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Shares withheld for taxes | −157 | $293.26 | $46K | 561.44 |
| 2017-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Grant or award | +2,730 | 3,291.44 | ||
| 2017-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Exercise or conversion · Restricted Stock Unit | −481 | 2,055 |
Page 62 of 73 · 1,456 trades